Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
Sanam LoghaviNaveen PemmarajuRashmi Kanagal-ShamanaMeenakshi MehrotraL Jeffrey MedeirosRaja LuthraPei LinYang O HuhHagop M KantarjianJorge E CortesSrdan VerstovsekKeyur P PatelPublished in: Blood (2015)